Parallel Advisors’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $75.8K | Hold |
1,053
| – | – | ﹤0.01% | 1749 |
|
|
2025
Q4 | $44.5K | Hold |
1,053
| – | – | ﹤0.01% | 1900 |
|
|
2025
Q3 | $59.9K | Hold |
1,053
| – | – | ﹤0.01% | 1689 |
|
|
2025
Q2 | $27.2K | Sell |
1,053
-2
| -0.2% | -$22 | ﹤0.01% | 2044 |
|
|
2025
Q1 | $10.8K | Hold |
1,055
| – | – | ﹤0.01% | 2407 |
|
|
2024
Q4 | $14.7K | Hold |
1,055
| – | – | ﹤0.01% | 2272 |
|
|
2024
Q3 | $20.6K | Hold |
1,055
| – | – | ﹤0.01% | 2083 |
|
|
2024
Q2 | $19.6K | Hold |
1,055
| – | – | ﹤0.01% | 1995 |
|
|
2024
Q1 | $14.8K | Hold |
1,055
| – | – | ﹤0.01% | 2138 |
|
|
2023
Q4 | $8.94K | Hold |
1,055
| – | – | ﹤0.01% | 2334 |
|
|
2023
Q3 | $9.42K | Hold |
1,055
| – | – | ﹤0.01% | 2233 |
|
|
2023
Q2 | $9.1K | Hold |
1,055
| – | – | ﹤0.01% | 2207 |
|
|
2023
Q1 | $11.1K | Sell |
1,055
-66
| -6% | -$2K | ﹤0.01% | 2084 |
|
|
2022
Q4 | $38K | Sell |
1,121
-73
| -6% | -$3.53K | ﹤0.01% | 1399 |
|
|
2022
Q3 | $57K | Buy |
1,194
+15
| +1% | +$892 | ﹤0.01% | 1209 |
|
|
2022
Q2 | $67K | Buy |
1,179
+49
| +4% | +$3.09K | ﹤0.01% | 1119 |
|
|
2022
Q1 | $94K | Sell |
1,130
-38
| -3% | -$5.62K | ﹤0.01% | 1015 |
|
|
2021
Q4 | $237K | Buy |
1,168
+23
| +2% | +$4.99K | 0.01% | 678 |
|
|
2021
Q3 | $308K | Buy |
1,145
+25
| +2% | +$6.01K | 0.01% | 561 |
|
|
2021
Q2 | $288K | Sell |
1,120
-3
| -0.3% | -$830 | 0.01% | 551 |
|
|
2021
Q1 | $337K | Buy |
1,123
+4
| +0.4% | +$1.25K | 0.02% | 460 |
|
|
2020
Q4 | $285K | Sell |
1,119
-27
| -2% | -$6.98K | 0.02% | 479 |
|
|
2020
Q3 | $285K | Buy |
1,146
+82
| +8% | +$25.8K | 0.02% | 440 |
|
|
2020
Q2 | $369K | Sell |
1,064
-3
| -0.3% | -$936 | 0.02% | 368 |
|
|
2020
Q1 | $285K | Buy |
1,067
+18
| +2% | +$5.57K | 0.02% | 362 |
|
|
2019
Q4 | $340K | Buy |
1,049
+5
| +0.5% | +$1.45K | 0.03% | 369 |
|
|
2019
Q3 | $285K | Hold |
1,044
| – | – | 0.02% | 387 |
|
|
2019
Q2 | $557K | Buy |
1,044
+4
| +0.4% | +$2.01K | 0.05% | 220 |
|
|
2019
Q1 | $524K | Hold |
1,040
| – | – | 0.06% | 216 |
|
|
2018
Q4 | $512K | Hold |
1,040
| – | – | 0.07% | 183 |
|
|
2018
Q3 | $951K | Sell |
1,040
-2
| -0.2% | -$1.71K | 0.12% | 139 |
|
|
2018
Q2 | $763K | Buy |
1,042
+5
| +0.5% | +$5.76K | 0.11% | 138 |
|
|
2018
Q1 | $1.65M | Buy |
+1,037
| New | +$1.34M | 0.26% | 70 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Parallel Advisors's NKTR Position: Q1 2026 in Review
Parallel Advisors held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 1,053 shares worth $75.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.
Parallel Advisors first reported a position in NKTR in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.65M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Parallel Advisors held 1,053 shares of Nektar Therapeutics worth $75.8K as of Q1 2026.
- Parallel Advisors left its Nektar Therapeutics share count unchanged in Q1 2026.
- Nektar Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1749 holding.
- Parallel Advisors first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Parallel Advisors's Nektar Therapeutics position peaked at $1.65M in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.